权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nanoscale Encapsulation for Fragment Based Drug Discovery

用于基于片段的药物发现的纳米级封装

基本信息

批准号：
9241998
负责人：
A. JOSHUA WAND
金额：
$ 17.51万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-03-10 至 2018-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9241998
关键词：
Affinity Alkanes Behavior Binding Chemicals Complex Confined Spaces Crystallization Crystallography Data Detection Dihydrofolate Reductase Dimensions Drug Targeting Encapsulated Enzymes Face Fluorescence Goals HIV Heteronuclear NMR Human In Vitro Individual Inferior Lead Libraries Ligand Binding Ligands Lipids Liquid substance Malignant neoplasm of prostate Mass Spectrum Analysis Membrane Methodology Methods Micelles Modification Morphologic artifacts Muramidase NMR Spectroscopy Nucleic Acids Performance Pharmaceutical Preparations Process Property Proteins Resistance Resolution Resources Sampling Solvents System Techniques Technology Testing Time Translations Validation Viscosity Water antimicrobial aqueous base biophysical techniques combinatorial chemistry comparative cost design drug discovery experimental study flexibility high throughput screening human disease hydrophilicity improved innovation interest lipophilicity member mutant nanoscale particle public health relevance screening small molecule tool

项目摘要

DESCRIPTION (provided by applicant): Over the past two decades high-throughput screening of protein-ligand interactions has evolved to become a central tool in the process of drug discovery. The very high-throughput in vitro screening (HTS) strategies are generally based on detection of ligand-binding using highly sensitive spectroscopic techniques such as fluorescence and, more recently, mass spectrometry. These types of approaches typically fail to reveal structural context for the protein-ligand complexes that are detected. For this reason, NMR-based screening, though of lower throughput, has emerged as an important contributor especially for post facto validation of HTS "hits." Recently, the design of screening libraries has become more sophisticated. This is particularly true with the fragment-based drug discovery libraries developed over the past decade or so. These libraries are designed to take advantage of advances in combinatorial chemistry with the goal of expanding the flexibility of taking a "hit" to a "lead" compound. Unfortunately, fragment-type ligands are inherently weak binders. This introduces a considerable cost in material (in order to reach concentrations necessary to detect binding) and an increased likelihood of false positive binding through non-specific interactions. This proposal will develop a strategy that will largely eliminate both of these concerns. It is based on the nanoscale properties of the reverse micelle. Utilizing the reverse micelle as a confined space, we anticipate being able to 1) efficiently detect weak specific binding; 2) reduce or eliminate non-specific binding; 3) significantly reduce the amount of ligand and protein required; and, most importantly, 4) enter a region of chemical space that is highly desired but difficult to access using existing screening strategies (i.e. weak hydrophilic binders). These advances rely on our recently developed ability to create solutions of individual protein molecules encapsulated within the nanoscale water core of reverse micelles. We will develop this screening strategy for high-resolution solution NMR spectroscopy as well as in a HTS context using fluorescence. Preliminary results indicate the feasibility of this approach. Several proteins of biomedical interest will be used to develop and test the use of nanoscale encapsulation to enhance the discovery of low affinity binders from a fragment library. Dihydrofolate reductase, a historical drug target, will be used to develop many of the strategies. A human aldoketoreductase enzyme (AKR1c3), currently a target for prostate cancer, will also be screened to demonstrate the utility of the approach for large soluble proteins. The myristoylated HIV matrix protein will be examined in its lipid extruded membrane-anchored state and will be representative of a class of proteins that have thus far generally eluded satisfactory screening using more standard methods. In summary, the studies proposed here will demonstrate a significant enhancement in screening of fragment libraries using nanoscale encapsulation and may lead to the discovery of initial compounds directed at these targets related to important human diseases.